文献摘要1.相容性，免疫方面ClinMater.1992;9(3-4):155-62.Clinicaluseofinjectablebovinecollagen:adecadeofexperience.KeefeJ1,WaukL,ChuS,DeLustroF.AuthorinformationAbstractBovinecollagenhaslongbeenrecognizedasasafe,highlybiocompatiblematerial.In1981and1985,twoinjectablefibrillarsuspensionsofpurifiedbovinedermalcollagen,ZydermandZyplastcollagenimplant,werecommerciallylaunchedintheUSAforuseinsofttissuecontourirregularities.Sincethattimemorethan750000patientshavebeentreatedwithZydermand/orZyplastcollagenimplantsinternationally.Adversereactionstobovinecollagenimplantsoccurinasmallpercentageoftreatedpatients.Themostprevalentadversereactionislocalizedhypersensitivityattreatmentsites,occurringin3%ofskintestedpatientsand1to2%ofthetreatedpatients.Thesereactionsresolvewithtimeastheimplantmaterialisresorbedbythehost.Circulatingantibodiestobovinecollagencanbedemonstratedintheseraofamajorityofpatients(90-100%)withlocalhypersensitivity.TheseantibodiesarespecificforbovinecollagenanddonotcrossreactwithhumantypeI,IIorIIIcollagen.Althoughthepresenceofahumoralimmuneresponsetobovinecollagencanbeassociatedwithlocalizedsymptomsofhypersensitivity,antibodiestobovinecollagencanalsobedemonstratedintheabsenceofanyclinicalmanifestation.PMID:10171198[PubMed-indexedforMEDLINE]牛胶原长时间被视为一种安全的高度生物相容性材料。在1981年和1985年，两个可注射原纤化悬浮液的纯化牛真皮胶原，Zyderm和Zyplast胶原蛋白植入体，被商业化推出在美国在软组织轮廓不规则中使用。从那以后时间超过750000名病人进行治疗与Zyderm和Zyplast胶原蛋白植入国际。牛胶原植入物的不良反应发生在治疗的患者的一小部分。最常见的不良反应是局部超敏反应地点治疗，3%的皮肤测试，患者和1到2%的治疗的患者中出现。这些反应解决随着时间的推移，植入材料被吸收由主机。循环到牛胶原抗体可以证明多数患者（90-100%）的血清中与当地的超敏反应。这些抗体为牛胶原是具体和交叉反应不与人类类型、II或III胶原蛋白。虽然牛胶原体液免疫反应的存在可以与本地化的过敏症状，还可在没有任何临床表现证明牛胶原的抗体。JAmAcadDermatol.1984Apr;10(4):652-8.Delayedskintestreactiontoinjectablecol...
